Skip to main content

Dexcom G7 CGM Trial is Now Recruiting

By Albert Cai

Participants with type 1 or type 2 diabetes will wear Dexcom’s next-generation continuous glucose monitor for ten days to evaluate its safety and accuracy.

As of March 31, 2021 the trial is fully enrolled and no longer recruiting.

Clinical Trials Identifier: NCT04794478

Trial name: Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System

Diabetes type: Type 1 and type 2 diabetes

What is the trial testing? What is Dexcom G7?

The trial will test the safety and performance of Dexcom G7, Dexcom’s next-generation continuous glucose monitor (CGM). Like the current Dexcom G6 system, G7 is worn on the arm or abdomen and measures the user’s glucose values every five minutes. Similar to G6, G7 can be worn for ten days and does not require any fingerstick calibrations. However, G7 is smaller than the G6 sensor and comes in a single piece, while Dexcom G6 has separate sensor and transmitter pieces that must be clicked together. The trial hopes to show that the G7 accurately reports glucose levels.

What will the trial measure?

Participants in the trial will wear the G7 CGM for ten days. On select days during that time, participants will have their blood drawn in the hospital every fifteen minutes. The blood samples will be sent to a large, scientific analyzer for comparison against G7’s glucose measurements. Participants will report any effects that they experience from using the device.

Are you interested in participating?

The trial will be run at 13 clinical sites across the US, all of which are currently recruiting. In total, the study expects to enroll about 500 participants with type 1 or type 2 diabetes over the age of 2. Clinical sites are located in California, Colorado, Idaho, Massachusetts, Texas, Utah, and Virginia.

For more information, contact: Stayce Beck (stayce.beck@dexcom.com) or Kathleen Hurst (khurst1@dexcom.com).

Share this article